Fluicell AB Logo

Fluicell AB

Developing bioprinted tissues for regenerative medicine and advanced drug screening.

FLUI | ST

Overview

Corporate Details

ISIN(s):
SE0010831321 (+1 more)
LEI:
549300R9LVFVFDTW5Y96
Country:
Sweden
Address:
Flöjelbergsgatan 8c, 431 37 Mölndal
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Fluicell AB is a biotechnology company specializing in single-cell biology and high-precision tissue engineering. The company develops solutions for regenerative medicine and drug screening through its groundbreaking Nexocyte™ platform, which is based on its patented, high-resolution Biopixlar™ single-cell bioprinting technology. Fluicell's primary focus is creating precision-engineered, transplantable tissues to treat diseases with significant unmet needs, with an initial goal to develop a cure for type 1 diabetes. In parallel, the Nexocyte platform generates advanced tissue models for pharmaceutical partners to enhance drug screening, particularly for cardiac and kidney toxicity. The company also commercializes a portfolio of research tools, including the BioPen® and Dynaflow® systems, that support single-cell research globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Fluicell AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fluicell AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fluicell AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sweden
MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland
MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland
MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany
MOR
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel
NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden
ONCOZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.